Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01380106 · OUTCOME

Duration Until Best Response (at Least MR or Minimal Response)

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma · Source last updated 2021-01-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
95% Confidence Interval
Time frame
Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.

What was measured

Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).

Analysis population: 33

Groups in this outcome

Lenalidomide 25mg

Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle

Lenalidomide 15mg

Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide 25mg16
Lenalidomide 15mg17

Reported measurements

Source class 1
Values in Days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Lenalidomide 25mg280.4Not reported86.6474.3Not reported
Lenalidomide 15mg145.5Not reported75.7215.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        86.6
        upper Limit
        474.3
        value
        280.4
      2. group Id
        OG001
        lower Limit
        75.7
        upper Limit
        215.3
        value
        145.5
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      17
    units
    Participants
description
Number of days between the first day of the first cycle to best M-protein response, at least Minimal Response or higher (Partial Response, Very Good Partial Response, near Complete Response, Complete Response).
dispersion Type
95% Confidence Interval
groups
  1. description
    Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle Lenalidomide 25mg: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
    id
    OG000
    title
    Lenalidomide 25mg
  2. description
    Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle Lenalidomide 15mg: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
    id
    OG001
    title
    Lenalidomide 15mg
param Type
MEAN
population Description
33
reporting Status
POSTED
time Frame
Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.
title
Duration Until Best Response (at Least MR or Minimal Response)
type
PRIMARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice